TBCRC 049 UAB 1794: A Phase II Non-randomized Study to Assess the Safety and Efficacy of the Combination of Tucatinib and Trastuzumab and Capecitabine for Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer


Total Award Amount

  • 53238.00
  • Direct Costs

  • 40952.00
  • Sponsor Award Id

  • Contributor

  • Louis Nabors M.D.   Investigator